Of the six hundred odd AERs (Adverse Event Reports) investigated,
The most frequent AERs were hemorrhage (n = 237) and infection (66). Hemorrhages included 1 fatal, 42 life threatening, and 168 serious cases; 68 required transfusions. Infections included 7 cases of septic shock (3 fatal, 4 life threatening) and 43 cases requiring parenteral antibiotics. Surgical interventions were required in 513 cases (235 emergent, 278 nonemergent). Emergent cases included 17 ectopic pregnancies (11 ruptured). Second trimester viability was documented in 22 cases (9 lost to follow-up, 13 documented fetal outcome). Of the 13 documented cases, 9 were terminated without comment on fetal morphology, 1 was enrolled in fetal registry, and 3 fetuses were diagnosed with serious malformations, suggesting a malformation rate of 23%.
In lay terms, you’re likely to bleed, require surgery or becoming infected, and there’s a chance that it won’t abort the baby anyway. Of the babies hit with the drug but not aborted, roughly a quarter are deformed by the drug.
At least 5 women have been unequivocally killed by the side-effects, and one has to wonder how many times more dead women didn’t report using the drug, or their doctors didn’t make the connection. The study authors comment:
AERs relied upon by the FDA to monitor mifepristone’s postmarketing safety are grossly deficient due to extremely poor quality.
Last year, the packaging was altered in Canada and the US to include a warning (like a cigarette packet) that this stuff can kill you or make you very ill. Does anyone know if Australian packaging was similarly modified? Can anyone see a pharma corp rushing to do so without regulatory intervention?